<DOC>
	<DOCNO>NCT02286284</DOCNO>
	<brief_summary>Introduction Preeclampsia multifactorial disease responsible important adverse maternal perinatal outcome . Recently , suggest soluble fms-like tyrosine kinase 1 , s-Flt1 , induce preeclampsia-like phenotype experimental model circulates elevate level human preeclampsia . The aim study see whether removal s-Flt1 may improve perinatal death woman early severe preeclampsia le 26 week ' gestation Patients method Phase II trial . Women singleton pregnancy severe preeclampsia 23-256/7 week ' gestation . Women 18 year , multiple , severe fetal growth restriction ( le 5th centile ) , abnormal fetal heart rate , maternal complication ( abruption , eclampsia , HELLP syndrome , pulmonary edema , DIC , liver hematoma ) exclude study . After blood pressure maternal stabilization , woman approach information agree , sign trial consent . Women twice weekly extracorporeal removal s-Flt1 34 week ' gestation . Primary endpoint success procedure : baby alive alive 6 month hospitalize Statistical procedure Simon minimax plan ; P0 : 60 % , P1 , 90 % , alpha error : 5 % , beta power ; 90 % . First step : number 8 patient . If success equal less 5 , study stop . Second step : success 6 , study continue 9 patient . Overall , maximum 17 patient include . The final success extracorporeal removal s-Flt1 consider 14 baby alive alive 6 month hospitalize .</brief_summary>
	<brief_title>Usefulness Extracorporeal Removal sFLT-1 Women With Very Early Severe Preeclampsia</brief_title>
	<detailed_description>Introduction Preeclampsia multifactorial disease responsible important adverse maternal perinatal outcome . Recently , suggest soluble fms-like tyrosine kinase 1 , s-Flt1 , induce preeclampsia-like phenotype experimental model circulates elevate level human preeclampsia . The aim study see whether removal s-Flt1 may improve perinatal death woman early severe preeclampsia le 26 week ' gestation Patients method Phase II trial . Women singleton pregnancy severe preeclampsia 23-256/7 week ' gestation . Women 18 year , multiple , severe fetal growth restriction ( le 5th centile ) , abnormal fetal heart rate , maternal complication ( abruption , eclampsia , HELLP syndrome , pulmonary edema , DIC , liver hematoma ) exclude study . After blood pressure maternal stabilization , woman approach information agree , sign trial consent . They admit department Renal intensive care Tenon Hospital . LDL apheresis perform twice weekly , 90 minute per session , use DALI 750 Kit ART device ( Fresenius ) . sFlt1 measure peripheral blood session . The treatment end delivery indicate ( whether threaten complication viable term pregnancy achieve ) . Primary endpoint success procedure : live born baby alive 6 month birth . Secondary endpoint : day pregnancy prolongation , blood pressure apheresis , fetal heart rate monitoring apheresis , maternal level s-Flt1 , PlGF , s-endoglin . Maternal adverse outcome : eclampsia , HELLP syndrome , DIC , pulmonary edema , abruption placenta , renal failure . Neonatal outcome : gestational age delivery , birth weight , Apgar score , patent ductus arteriosus , RDS , PVL , IVH , NEC , day NICU . Statistical procedure Simon minimax plan ; P0 : 60 % , P1 , 90 % , alpha error : 5 % , beta power ; 90 % . First step : number 8 patient . If success equal less 5 , study stop . Second step : success 6 , study continue 9 patient . Overall , maximum 17 patient include . The final success extracorporeal removal s-Flt1 consider 14 baby alive 6 month birth</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<criteria>Severe preeclampsia le 26 week ' gestation Singleton pregnancy Signed consent Multiple pregnancy Gestational age 26 week ' gestation Estimated foetal weight diagnosis &lt; 5th percentile Abnormal fetal heart rate entry , feasible ( &gt; 24 week ' gestation ) Maternal complication diagnosis : Uncontrolled blood pressure , HELLP syndrome , abruption , eclampsia pulmonary edema , renal failure , liver hematoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Early severe preeclampsia</keyword>
	<keyword>Angiogenic factor</keyword>
	<keyword>Apheresis</keyword>
</DOC>